menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Patient dies after receiving Sarepta’s DMD gene therapy Elevidys

    FIERCE PHARMA

    Sarepta Opens Applications For 8th Route 79 Duchenne Scholarship

    BUSINESSWIRE

    Sarepta Announces Q4, Full-Year 2024 Results & Developments

    BUSINESSWIRE

    Sarepta Announces Inaugural $600 M Senior Secured Credit Facility

    BUSINESSWIRE

    Sarepta To Announce Q4 & Full-Year 2024 Results

    BUSINESSWIRE

    Arrowhead & Sarepta Close Global License Agreement

    BUSINESSWIRE

    Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

    BUSINESSWIRE

    Sarepta`s Embark Study Part 2 Shows Elevidys Benefits In DMD

    BUSINESSWIRE

    Sarepta Therapeutics Reports Q4, Full-Year 2024 Net Revenue

    BUSINESSWIRE

    Sarepta Therapeutics to Present at 43rd J.P. Morgan Conference

    BUSINESSWIRE

    Sarepta Announces Inducement Grants Under Nasdaq LR 5635(c)(4)

    BUSINESSWIRE

    Sarepta Wins 115.2 M US Drug Patent Verdict from Nippon Shinyaku

    REUTERS

    Sarepta Completes Enrollment in SRP-9003 Ph 3 Study for LGMD2E/R4

    BUSINESSWIRE

    FDA`s Accelerated Approval Drives Momentum for Fatal Diseases

    BIOSPACE

    Sarepta Announces Inducement Grants Under Nasdaq LR 5635(c)(4)

    BUSINESSWIRE

    Sarepta, Arrowhead ink $1B-plus deal for seven programs

    FIERCE BIOTECH

    Sarepta axes late-phase DMD drug over safety signal

    FIERCE BIOTECH

    Sarepta`s Elevidys blows sales expectations out of the water

    FIERCE PHARMA

    Sarepta Therapeutics Announces Q3 2024 Results & Developments

    BUSINESSWIRE

    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rule

    BUSINESSWIRE

    Sarepta Therapeutics Q3 2024 Financial Results Announcement

    BUSINESSWIRE

    Sarepta Announces Inducement Grants Under Nasdaq Rule

    BUSINESSWIRE

    Sarepta To Present At World Muscle Society Congress

    BUSINESSWIRE

    Sarepta Appoints Deirdre Connelly To Board

    BUSINESSWIRE

    Sarepta Therapeutics Announces 2024-25 Route 79 Duchenne Scholarship Recipients

    BUSINESSWIRE

    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rules

    BUSINESSWIRE

    Sarepta Therapeutics Reports Q2 2024 Results And Corporate Developments

    BUSINESSWIRE

    Sarepta Faces Lower Revenue For Duchenne Gene Therapy

    ENDPTS

    Sarepta Therapeutics Announces Inducement Grants

    BUSINESSWIRE

    Sanofi sues Sarepta, claiming Duchenne gene therapy Elevidys infringes 2 manufacturing patents

    FIERCE PHARMA

    Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results

    BUSINESSWIRE

    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule

    BUSINESSWIRE

    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)

    BUSINESSWIRE

    US FDA approves expanded use of Sarepta`s Duchenne gene therapy; shares jump

    REUTERS

    Great Point Partners acquires German CDMO Lyocontract

    FIERCE PHARMA

    Sarepta Announces Inducement Grants Per Nasdaq Rule

    BUSINESSWIRE

    Sarepta Seeks Label Expansion, Bigger Market for DMD Gene Therapy

    BIOSPACE

    Sarepta Therapeutics executive sells $508,900 in stock

    INVESTING

    Gene Therapy Pioneer Mendell Named To TIME100 Health List

    BUSINESSWIRE

    ICER pushes back on FDA`s potential of Sarepta`s gene therapy to full approval

    ENDPTS

    Sarepta Q1 2024 Results, Recent Corporate Developments

    BUSINESSWIRE

    FDA decision on Sarepta’s Duchenne gene therapy could come earlier than expected

    ENDPTS

    Sarepta Therapeutics Inducement Grants Under Nasdaq 5635(c)(4)

    BUSINESSWIRE

    Sarepta Therapeutics to Announce First Quarter 2024 Financial Results

    BUSINESSWIRE

    Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program

    PRESS RELEASE

    US spent $3B on DMD treatments

    ENDPTS

    Sarepta Therapeutics to Present at Upcoming Investor Conferences

    BUSINESSWIRE

    Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79

    PRESS RELEASE

    Elevidys gains steam amid Sarepta`s efforts to widen FDA label

    FIERCE PHARMA

    Sarepta Announces Fourth Quarter and Full-Year 2023 Financial Results

    BUSINESSWIRE

    Internal documents shed new light on Sarepta FDA decision

    ENDPTS

    Sarepta to Announce Fourth Quarter and Full-Year 2023 Financial Results

    BUSINESSWIRE

    Sarepta`s Elevidys expansion bid gets fast review without adcomm

    FIERCE PHARMA

    Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BUSINESSWIRE

    Sarepta Announces Positive Data from Part B of MOMENTUM, a Phase 2 of SRP-5051

    BUSINESSWIRE

    Sarepta Announces Positive Data from Phase 2 Study of SRP-5051

    PRESS RELEASE

    Sarepta Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003

    BUSINESSWIRE

    Sarepta Therapeutics Initiates Screening in Phase 3 Study of SRP-9003

    PRESS RELEASE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.